Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial
Conclusion: In sum, single-agent pembrolizumab was well tolerated as salvage therapy in a small cohort of patients with unresectable, locally advanced or metastatic penile SCC. Pembrolizumab produced an objective response in an MSI-H tumor, yet it did not control disease in two patients with MSS penile SCC. Rationale combination therapies, including pembrolizumab, warrant further investigation.Trial registration: ClinicalTrials.gov identifier:NCT02721732. Registered March 23, 2016.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Penile Cancer | Skin Cancer | Squamous Cell Carcinoma | Study